Todd Brady Buys Shares of Contineum Therapeutics
Insider Todd Brady purchased 19,000 shares of Contineum Therapeutics on June 26.
Key Points
- On June 26, 2026, insider Todd Brady bought 19,000 shares of Contineum Therapeutics, Inc. (CTNM).
- Shares of CTNM traded near $13.36 on Saturday, with a market cap of $530.5 million and a forward P/E ratio not meaningful due to lack of profitability.
- Institutional investors like Janus Henderson Group and Millennium Management have adjusted their positions in Contineum Therapeutics recently.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 26, 2026, Todd Brady, an insider at Contineum Therapeutics, Inc. (NasdaqGS: CTNM), purchased 19,000 shares of the company. This transaction was not conducted under a prearranged trading plan.
Insider Buying and Selling at Contineum Therapeutics, Inc.
Several insiders at Contineum Therapeutics, including Todd Brady, purchased 19,000 shares each on June 26, 2026. These transactions were not part of a Rule 10b5-1 plan, indicating the buys were discretionary.
Other Institutional Activity in Contineum Therapeutics
Janus Henderson Group PLC increased its holdings in Contineum Therapeutics by 285,857 shares, bringing its total to 2,734,836 shares valued at approximately $35.6 million, reflecting an 11.7% increase. Millennium Management LLC also made a significant move, boosting its position by 704,762 shares to a total of 1,535,449 shares, worth around $20.1 million, marking an 84.8% increase. On the other hand, Franklin Resources Inc. reduced its stake by 40,140 shares to 1,839,227 shares, valued at about $24.0 million, a 2.1% decrease.
Contineum Therapeutics, Inc. Stock Down 16.8%
Shares of Contineum Therapeutics traded near $13.36 on Saturday. The company has a market cap of approximately $530.5 million. Its forward P/E ratio is not meaningful as the company is not currently profitable. The stock's 52-week range is between $3.72 and $16.33, with a 50-day moving average of $13.02 and a 200-day moving average of $12.53. The beta is 0.89, suggesting lower volatility compared to the broader market.
$CTNM stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On May 14, 2026, Morgan Stanley maintained its hold rating on Contineum Therapeutics with a price target of $16.0. Earlier, on March 6, 2026, Baird maintained a buy rating with a target of $20.0. RBC Capital also maintained a buy rating on November 21, 2025, with a target of $22.0. The consensus among analysts is a strong buy, with a mean target price of $22.33 based on six opinions.
About Contineum Therapeutics
Contineum Therapeutics, Inc. is a biopharmaceutical company based in San Diego, California. It focuses on developing small molecule therapies for neuroscience, inflammation, and immunology. Its lead product, PIPE-791, targets idiopathic pulmonary fibrosis and chronic pain. Another key product, PIPE-307, is aimed at treating depression and multiple sclerosis. The company was founded in 2009 and is led by CEO Mr. Carmine N. Stengone.
Bottom Line
Insider purchases like Todd Brady's can be a sign of confidence in Contineum Therapeutics' prospects. Investors often watch these transactions closely as they can provide insights into the company's future. Keep in mind, however, that these filings reflect past actions and may not indicate current positions or future intentions.
Get Contineum Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $CTNM, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.